The paradigm for prostate cancer treatment is evolving. While there is an increasing desire to manage low-risk cancers without aggressive treatment, there is also a need to identify high-risk cancers and treat appropriately. In this CAPcast interview, Dr. Sean Williamson, a surgical pathologist from the Henry Ford Health System, discusses the diagnostic challenges of evaluating prostate biopsies, the significance of neuroendocrine differentiation in prostate cancer, and recent consensus guidelines and classification schemes. Dr. Williamson and Dr. Giovanna Giannico will be teaching a course on this topic at CAP19, which will be held Sept. 21-25 in Orlando, Florida: https://capatholo.gy/2Vzqkm9.